Arbutus Biopharma Corporation ABUS Non-cash royalty revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's non-cash royalty revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's non-cash royalty revenue — revenue?
- Arbutus Biopharma Corporation (ABUS) reported non-cash royalty revenue — revenue of $181K in Q1 2026.
- How has Arbutus Biopharma Corporation's non-cash royalty revenue — revenue changed year-over-year?
- Arbutus Biopharma Corporation's non-cash royalty revenue — revenue decreased by 59.6% year-over-year, from $448K to $181K.
- What is the long-term trend for Arbutus Biopharma Corporation's non-cash royalty revenue — revenue?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's non-cash royalty revenue — revenue has grown at a -29.8% compound annual growth rate (CAGR), from $6.11M to $1.48M.
- What does non-cash royalty revenue — revenue mean?
- This metric represents the total revenue recognized from non-cash royalty arrangements associated with licensed intellectual property or technology platforms. It reflects the economic value derived from licensing agreements where consideration is received in forms other than direct cash payments. Investors use this to assess the monetization potential of the company's proprietary technology portfolio and the sustainability of non-operating revenue streams.